Disease · MONDO_0004947

B-cell acute lymphoblastic leukemia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. B-cell acute lymphoblastic leukemia. Diseases, record MONDO_0004947. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0004947

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: B-cell acute lymphoblastic leukemia; Open Targets
Open Targets ID: MONDO_0004947; Open Targets
Other names: B lymphoblastic leukemia/lymphoma, B-precursor acute lymphoblastic leukemia, precursor B lymphoblastic leukemia/lymphoma, precursor B-lymphoblastic lymphoma/leukemia; Open Targets
Disease Ontology: DOID:0080630; Disease Ontology
Disease Ontology: DOID:7061; Disease Ontology
NCI Thesaurus: C8936; NCI Thesaurus
Highest stage of its drugs: Approval, for 3 of its 47 drugs, from DailyMed, FDA and PMDA; Open Targets

Drugs47

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
BLINATUMOMAB	CHEMBL1742992	Antibody	Approval	PMDA	9	8	8	Drugs and targets
INOTUZUMAB OZOGAMICIN	CHEMBL2108611	Antibody drug conjugate	Approval	FDA	5	4	4	Drugs and targets
OBECABTAGENE AUTOLEUCEL	CHEMBL5095440	Gene	Approval	DailyMed	1	0	0	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 3	ClinicalTrials.gov	14	14	14	Drugs and targets
ETOPOSIDE	CHEMBL44657	Small molecule	Phase 3	ClinicalTrials.gov	7	7	7	Drugs and targets
VINCRISTINE	CHEMBL90555	Small molecule	Phase 3	ClinicalTrials.gov	7	7	7	Drugs and targets
FLUDARABINE	CHEMBL1568	Small molecule	Phase 3	ClinicalTrials.gov	6	6	6	Drugs and targets
METHOTREXATE	CHEMBL34259	Small molecule	Phase 3	ClinicalTrials.gov	6	6	6	Drugs and targets
CYTARABINE	CHEMBL803	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
RITUXIMAB	CHEMBL1201576	Antibody	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets

1 to 10 of 47

See all 47 drugs

Targets55

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
TOP2A	DNA topoisomerase 2-alpha	6	DNA topoisomerase II alpha inhibitor; DNA topoisomerase II inhibitor	Phase 3	https://conductscience.org/library/genes/7153	Drugs and targets
CD19	B-lymphocyte antigen CD19	5	B-lymphocyte antigen CD19 binding agent; B-lymphocyte antigen CD19 cross-linking agent	Approval	https://conductscience.org/library/genes/930	Drugs and targets
NR3C1	Glucocorticoid receptor	5	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets
CD22	B-cell receptor CD22	2	CD22 binding agent; CD22 inhibitor	Approval	https://conductscience.org/library/genes/933	Drugs and targets
CD3D	T cell surface glycoprotein CD3	2	T cell surface glycoprotein CD3 binding agent; T cell surface glycoprotein CD3 cross-linking agent	Approval	https://conductscience.org/library/genes/915	Drugs and targets
CD3E	T cell surface glycoprotein CD3	2	T cell surface glycoprotein CD3 binding agent; T cell surface glycoprotein CD3 cross-linking agent	Approval	https://conductscience.org/library/genes/916	Drugs and targets
CD3G	T cell surface glycoprotein CD3	2	T cell surface glycoprotein CD3 binding agent; T cell surface glycoprotein CD3 cross-linking agent	Approval	https://conductscience.org/library/genes/917	Drugs and targets
IMPDH1	Inosine-5'-monophosphate dehydrogenase (IMPDH)	2	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor	Phase 3	https://conductscience.org/library/genes/3614	Drugs and targets
IMPDH2	Inosine-5'-monophosphate dehydrogenase (IMPDH)	2	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor	Phase 3	https://conductscience.org/library/genes/3615	Drugs and targets
MS4A1	B-lymphocyte antigen CD20	2	B-lymphocyte antigen CD20 binding agent	Phase 3	https://conductscience.org/library/genes/931	Drugs and targets

1 to 10 of 55

See all 55 targets

Trials27

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02101853	Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia	Phase 3	669	2022-12-06	Recurrent B Acute Lymphoblastic Leukemia	ASPARAGINASE, BLINATUMOMAB, CYCLOPHOSPHAMIDE, CYTARABINE, DEXAMETHASONE, ETOPOSIDE, HYDROCORTISONE, LEUCOVORIN CALCIUM, MERCAPTOPURINE, METHOTREXATE, MITOXANTRONE HYDROCHLORIDE, PEGASPARGASE, THIOGUANINE, VINCRISTINE SULFATE	Its record names the disease	ClinicalTrials.gov
NCT02614066	A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)	Phase 1/2	125	2021-11-29	Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia	BREXUCABTAGENE AUTOLEUCEL, CYCLOPHOSPHAMIDE, FLUDARABINE	Its record names the disease	ClinicalTrials.gov
NCT04307134	Besponsa Post Marketing Surveillance Study		108	2025-12-31	Hematologic Malignancy	INOTUZUMAB OZOGAMICIN	Its record names the disease	ClinicalTrials.gov
NCT00057811	Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma	Phase 2	97	2014-08-22	Childhood Burkitt Lymphoma, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma, Stage I Childhood Large Cell Lymphoma, Stage I Childhood Small Noncleaved Cell Lymphoma, Stage II Childhood Large Cell Lymphoma, Stage II Childhood Small Noncleaved Cell Lymphoma, Stage III Childhood Large Cell Lymphoma, Stage III Childhood Small Noncleaved Cell Lymphoma, Stage IV Childhood Large Cell Lymphoma, Stage IV Childhood Small Noncleaved Cell Lymphoma, Untreated Childhood Acute Lymphoblastic Leukemia	CYCLOPHOSPHAMIDE, CYTARABINE, DOXORUBICIN HYDROCHLORIDE, ETOPOSIDE, FILGRASTIM, LEUCOVORIN CALCIUM, METHOTREXATE, METHYLPREDNISOLONE, RASBURICASE, RITUXIMAB, VINCRISTINE	Its record names the disease	ClinicalTrials.gov
NCT03959085	Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy	Phase 3	5,951		B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia, Mixed Phenotype Acute Leukemia, Testicular Leukemia	BLINATUMOMAB, INOTUZUMAB OZOGAMICIN	Its record names the disease	ClinicalTrials.gov
NCT02881086	Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment	Phase 3	1,023		Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma	ASPARAGINASE, CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DEXAMETHASONE, DOXORUBICIN, ETOPOSIDE, FLUDARABINE, IDARUBICIN, IMATINIB, MERCAPTOPURINE, METHOTREXATE, NELARABINE, PREDNISOLONE, RITUXIMAB, VINCRISTINE, VINDESINE	Its record names the disease	ClinicalTrials.gov
NCT02405676	BNHL-2015 for Children or Adolescents in China	Phase 2/3	200		Mature B-cell Non-Hodgkin Lymphoma	CYCLOPHOSPHAMIDE, CYTARABINE, ETOPOSIDE, METHOTREXATE, PREDNISONE, RITUXIMAB, VINCRISTINE	Its record names the disease	ClinicalTrials.gov
NCT06237192	MRD-associated Non-intensive But Non-interruptive Treatment of Ph-negative Acute Lymphoblastic Leukemia Adult Patients	Not applicable	200		Precursor Cell Lymphoblastic Leukemia-Lymphoma	BLINATUMOMAB, VENETOCLAX	Its record names the disease	ClinicalTrials.gov
NCT07003737	Blinatumomab Intensification for MRD-Negative Acute B-Cell Lymphoblastic Leukemia Before Allogeneic Hematopoietic Stem Cell Transplantation	Not applicable	114		Acute Lymphoblastic Leukemia, B-precursor	BLINATUMOMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT04318678	CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)	Phase 1	108		AML/MDS, B-ALL, T-ALL, BPDCN	CYCLOPHOSPHAMIDE, FLUDARABINE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 27

See all 27 trials

Comparisons in its trials1

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial
Group B (Chemotherapy, Protective Therapy, Monoclonal Antib.) vs Group C (Chemotherapy, Monoclonal Antibody Therapy): serious adverse events	2 of 46	6 of 42	88	NCT00057811

Source Trial comparisons

Papers from its trials21

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
34097852	RESULT	1	PubMed
33827116	RESULT	1	PubMed
22940833	RESULT	1	PubMed
20516455	RESULT	1	PubMed
15486066	RESULT	1	PubMed
10552938	RESULT	1	PubMed
42988007	DERIVED	1	PubMed
42477805	DERIVED	1	PubMed
41671463	DERIVED	3	PubMed
40568722	DERIVED	1	PubMed

1 to 10 of 21

See all 21 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0004947

GET https://conductscience.org/api/diseases/v1/MONDO_0004947/drugs?page=2

API reference For AI assistants